Compare NRG Energy Inc (NRG) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Organon & Co. Common Stock — how do they compare? NRG Energy Inc trades at $99.8 (market cap $21.20B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: NRG Energy Inc is far larger — about 5.9× Organon & Co. Common Stock's market cap, and NRG Energy Inc pays the higher dividend (1.88%). Which is the better fit depends on your goals — on Pluang, investors hold NRG Energy Inc for 63 Days and Organon & Co. Common Stock for 0 Days on average.
| NRG | OGN | |
|---|---|---|
Market Cap | $21.20B | $3.61B |
Volume | 2,487,856 | 1,808,049 |
Sector | Utilities | Health |
52-Week High | $184.03 | $13.81 |
52-Week Low | $95.23 | $5.70 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $45.15B | $11.03B |
Dividend Yield | 1.88% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $107.18, up 0.76% on the day, with a neutral technical signal and bearish moving averages. The company reported mixed Q2 2026 earnings, missing estimates but showing strong EBITDA growth of 34% year-over-year. Recent news highlights a major 1.2 GW Texas data center power project and potential acquisition interest in a West Virginia coal plant. Analyst consensus remains strongly bullish with a $202.90 price target, though recent quarters have seen earnings misses.
The outlook is supported by strategic growth initiatives and solid cash flow, but risks include rising debt levels and execution challenges. The stock offers potential upside from analyst targets, but investors face volatility from earnings inconsistency and high leverage. The current valuation appears reasonable with a P/E of 27.91 and P/S of 0.66, balancing growth prospects with financial risk.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
